Cost-effectiveness of SARS-CoV-2 self-testing at routine gatherings to minimize community-level infections in lower-middle income countries: A mathematical modeling study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 06 12 2023
accepted: 13 09 2024
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 4 10 2024
Statut: epublish

Résumé

Places of worship serve as a venue for both mass and routine gathering around the world, and therefore are associated with risk of large-scale SARS-CoV-2 transmission. However, such routine gatherings also offer an opportunity to distribute self-tests to members of the community to potentially help mitigate transmission and reduce broader community spread of SARS-CoV-2. Over the past four years, self-testing strategies have been an impactful tool for countries' response to the COVID-19 pandemic, especially early on to mitigate the spread when vaccination and treatment options were limited. We used an agent-based mathematical model to estimate the impact of various strategies of symptomatic and asymptomatic self-testing for a fixed percentage of weekly routine gatherings at places of worship on community transmission of SARS-CoV-2 in Brazil, Georgia, and Zambia. Testing strategies assessed included weekly and bi-weekly self-testing across varying levels of vaccine effectiveness, vaccine coverage, and reproductive numbers to simulate developing stages of the COVID-19 pandemic. Self-testing symptomatic people attending routine gatherings can cost-effectively reduce the spread of SARS-CoV-2 within places of worship and the community, resulting in incremental cost-effectiveness ratios of $69-$303 USD. This trend is especially true in contexts where population level attendance at such gatherings is high, demonstrating that a distribution approach is more impactful when a greater proportion of the population is reached. Asymptomatic self-testing of attendees at 100% of places of worship in a country results in the greatest percent of infections averted and is consistently cost-effective but remains costly. Budgetary needs for asymptomatic testing are expensive and likely unaffordable for lower-middle income countries (520-1550x greater than that of symptomatic testing alone), promoting that strategies to strengthen symptomatic testing should remain a higher priority.

Identifiants

pubmed: 39365802
doi: 10.1371/journal.pone.0311198
pii: PONE-D-23-40614
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0311198

Informations de copyright

Copyright: © 2024 Hansen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The views expressed in this manuscript are those of the authors and do not necessarily represent the official position of the WHO.

Auteurs

Megan A Hansen (MA)

Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Global Health, Boston University School of Public Health, Boston, MA, United States of America.

Alvin X Han (AX)

Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Joshua M Chevalier (JM)

Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Global Health, Boston University School of Public Health, Boston, MA, United States of America.

Ethan Klock (E)

Department of Global Health, Boston University School of Public Health, Boston, MA, United States of America.

Hiromi Pandithakoralage (H)

Department of Global Health, Boston University School of Public Health, Boston, MA, United States of America.

Alexandra de Nooy (A)

Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Tom Ockhuisen (T)

Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Sarah J Girdwood (SJ)

Health Economics and Epidemiology Research Office, University of the Witwatersrand, Johannesburg, South Africa.
FIND, Geneva, Switzerland.

Nkgomeleng A Lekodeba (NA)

Health Economics and Epidemiology Research Office, University of the Witwatersrand, Johannesburg, South Africa.

Shaukat Khan (S)

FIND, Geneva, Switzerland.

Helen E Jenkins (HE)

Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America.

Cheryl C Johnson (CC)

World Health Organization (WHO), Geneva, Switzerland.

Jilian A Sacks (JA)

World Health Organization (WHO), Geneva, Switzerland.

Colin A Russell (CA)

Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Brooke E Nichols (BE)

Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Global Health, Boston University School of Public Health, Boston, MA, United States of America.
FIND, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH